VAXCYTE, INC. Diluted Shares Outstanding (Weighted Average)
VAXCYTE, INC. (PCVX) reported Diluted Shares Outstanding (Weighted Average) of 144.49 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-05
- VAXCYTE, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 144.49M shares, a 6.22% increase year-over-year.
- VAXCYTE, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 139.51M shares, a 2.81% increase year-over-year.
- VAXCYTE, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 136.43M shares, a 0.91% increase year-over-year.
- VAXCYTE, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 136.20M shares, a 10.11% increase year-over-year.
- VAXCYTE, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 136.09M shares, a 11.55% increase from fiscal 2024.
- VAXCYTE, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 122.00M shares, a 25.57% increase from fiscal 2023.
- VAXCYTE, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 97.16M shares, a 49.75% increase from fiscal 2022.
- VAXCYTE, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 64.88M shares, a 24.95% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 144.49M shares 10-Q · filed 2026-08-05 | 142.01M shares 10-Q · filed 2026-08-05 | 140.14M shares derived: average of 3 quarters · filed 2026-08-05 | 139.16M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 139.51M shares 10-Q · filed 2026-05-06 | 137.97M shares derived: average of 2 quarters · filed 2026-05-06 | 137.38M shares derived: average of 3 quarters · filed 2026-05-06 | 137.04M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 136.43M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 136.31M shares derived: average of 2 quarters · filed 2026-02-24 | 136.22M shares derived: average of 3 quarters · filed 2026-08-05 | 136.09M shares 10-K · filed 2026-02-24 |
| 2025-09-30 | 136.20M shares 10-Q · filed 2025-11-04 | 136.12M shares derived: average of 2 quarters · filed 2026-08-05 | 135.98M shares 10-Q · filed 2025-11-04 | 135.78M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 136.03M shares 10-Q · filed 2026-08-05 | 135.86M shares 10-Q · filed 2026-08-05 | 135.64M shares derived: average of 3 quarters · filed 2026-08-05 | 132.65M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 135.69M shares 10-Q · filed 2026-05-06 | 135.45M shares derived: average of 2 quarters · filed 2026-05-06 | 131.53M shares derived: average of 3 quarters · filed 2026-05-06 | 127.96M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 135.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 129.45M shares derived: average of 2 quarters · filed 2026-02-24 | 125.38M shares derived: average of 3 quarters · filed 2026-02-24 | 122.00M shares 10-K · filed 2026-02-24 |
| 2024-09-30 | 123.69M shares 10-Q · filed 2025-11-04 | 120.48M shares derived: average of 2 quarters · filed 2025-11-04 | 117.60M shares 10-Q · filed 2025-11-04 | 113.79M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | 117.26M shares 10-Q · filed 2025-08-06 | 114.47M shares 10-Q · filed 2025-08-06 | 110.49M shares derived: average of 3 quarters · filed 2026-02-24 | 108.29M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | 111.69M shares 10-Q · filed 2025-05-07 | 107.11M shares derived: average of 2 quarters · filed 2026-02-24 | 105.30M shares derived: average of 3 quarters · filed 2026-02-24 | 103.49M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | 102.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 102.10M shares derived: average of 2 quarters · filed 2026-02-24 | 100.75M shares derived: average of 3 quarters · filed 2026-02-24 | 97.16M shares 10-K · filed 2026-02-24 |
| 2023-09-30 | 101.67M shares 10-Q · filed 2024-11-05 | 99.86M shares derived: average of 2 quarters · filed 2024-11-05 | 95.37M shares 10-Q · filed 2024-11-05 | 91.24M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | 98.06M shares 10-Q · filed 2024-08-06 | 92.17M shares 10-Q · filed 2024-08-06 | 87.76M shares derived: average of 3 quarters · filed 2025-02-25 | 81.32M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | 86.21M shares 10-Q · filed 2024-05-08 | 82.61M shares derived: average of 2 quarters · filed 2025-02-25 | 75.74M shares derived: average of 3 quarters · filed 2025-02-25 | 72.01M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | 79.01M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 70.50M shares derived: average of 2 quarters · filed 2025-02-25 | 67.27M shares derived: average of 3 quarters · filed 2025-02-25 | 64.88M shares 10-K · filed 2025-02-25 |
| 2022-09-30 | 61.99M shares 10-Q · filed 2023-11-06 | 61.40M shares derived: average of 2 quarters · filed 2023-11-06 | 60.17M shares 10-Q · filed 2023-11-06 | 58.29M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 60.82M shares 10-Q · filed 2023-08-08 | 59.19M shares 10-Q · filed 2023-08-08 | 57.06M shares derived: average of 3 quarters · filed 2024-02-27 | 55.84M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 57.55M shares 10-Q · filed 2023-05-08 | 55.18M shares derived: average of 2 quarters · filed 2024-02-27 | 54.18M shares derived: average of 3 quarters · filed 2024-02-27 | 53.51M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 52.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 52.50M shares derived: average of 2 quarters · filed 2024-02-27 | 52.17M shares derived: average of 3 quarters · filed 2024-02-27 | 51.92M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 52.19M shares 10-Q · filed 2022-11-07 | 51.85M shares derived: average of 2 quarters · filed 2022-11-07 | 51.63M shares 10-Q · filed 2022-11-07 | |
| 2021-06-30 | 51.51M shares 10-Q · filed 2022-08-08 | 51.34M shares 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | 29.55M shares 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |